Medtronic
Strategy for Business Development

Name: Joslin Gadde
Student ID: 20076078
Module Code: BMG921

Table of Contents

1.Introduction

1.1 Business Overview

Medtronic plc is a globally recognized leader in medical technology, employing over 95,000 individuals across more than 150 countries. Driven by the mission to "alleviate pain, restore health, and extend life," the company applies biomedical engineering to create transformative medical instruments and therapies. Its core business is segmented into major units, including Cardiovascular/Cardiac (devices like pacemakers), Diabetes (insulin pumps and glucose monitoring), Medical Surgical (advanced surgical tools), and Neuroscience (neuromodulation). Medtronic is strategically evolving beyond a traditional device manufacturer into a connected health provider through a significant digital transformation, leveraging cloud-based platforms, remote patient monitoring (IoMT), and predictive analytics to deliver personalized, insight-driven therapies and enhance patient care.



Fig 1: Operational Segments of Medtronic's Revenue FY25

1.2 Importance of Digital Transformation in Medical Devices

Digital transformation is reshaping medical devices, using AI, telehealth, and IoMT to deliver personalized, efficient care while reducing costs (Rossi and Rehman, n.d.). Market pressures and patient demand are driving MedTech firms like Medtronic to move beyond hardware toward connected, data-driven solutions.

1.3 Aim and Objectives of the Report

The aim of this report is to critically evaluate Medtronic's current business strategy using established strategic analysis tools and based on these insights, develop

a comprehensive digital transformation strategy supported by an implementation plan and reflective learning assessment.

Objective of the Report:

- Analyse Medtronic's internal and external environment using relevant strategic tools.
- Assess Medtronic's current strategic position and identify key challenges and opportunities.
- Develop a digital transformation strategy using tools such as the Ansoff Matrix, BCG Matrix, and business model disruption frameworks.
- Create a detailed implementation plan outlining resources, responsibilities, risks, budget, timeline, and success measures.
- Apply an appropriate reflective model to evaluate personal learning from the module.

TASK 1 – EVALUATION OF CURRENT BUSINESS STRATEGY

2.1 Overview of Medtronic's Current Corporate & Business Strategy

Medtronic's mission to "alleviate pain, restore health, and extend life" drives its focus on patient outcomes and innovation (Medtronic, 2025). Its diversified portfolio treating over 70 conditions reduces strategic risk (Medtronic, Key Facts, 2025). Strong innovation capacity—supported by 41,000+ patents and AI/robotics investment—enhances its technological leadership (Medtronic, AI and Robotics Hub, 2025). Partnerships with hospitals, governments, and NGOs expand global care access (Medtronic, Healthcare Access, 2025). Together, these strengths reinforce Medtronic's competitiveness and global impact.

2.2 PESTEL Analysis on Medtronic

Medtronic operates in a complex global environment shaped by political, economic, social, technological, environmental, and legal forces that require constant strategic adaptation (Nielsen, 2019). Politically, supportive healthcare policies and ageing populations increase device demand (Holland & Bátiz-Lazo, 2004), while AI adoption creates innovation opportunities.

However, stricter regulations such as EU MDR and FDA requirements increase compliance pressure, as seen in Philips' large-scale recalls. Economically, slow market growth, supply chain disruptions, and sustainability pressures challenge performance (Carter, 2018; Siddiqui, 2021), while competitors like Siemens Healthineers grow through digital subscription models. Socially, rising chronic disease needs and expectations for affordable, accessible care intensify competition (Andolina, Gavioli & Ancarani, 2023).

Technological change remains central, with AI, robotics, and digital health driving industry innovation (Medtronic, 2025). Competitors such as GE Healthcare's Edison platform demonstrate significant efficiency gains, reinforcing Medtronic's need to accelerate its digital ecosystem. Environmental expectations require stronger sustainability and waste reduction (Hovelling et al., 2024). Legally, FDA, MDR, and reimbursement rules shape market access and operational risks (Fox et al., 2024).

Overall, these external factors create both opportunities and pressures that influence Medtronic's global strategy.



Figure 1: Top Global Medical Equipment Companies in 2024

2.3 TWOS MATRIX ANALYSIS on Medtronic

The TOWS Matrix aligns strategy by linking internal strengths and weaknesses with external opportunities and threats. Medtronic can use its R&D strengths to expand into new regions and grow its home-based chronic care devices (Nielsen, 2019).

Strength-Opportunities (SO): -

Medtronic can use its R&D and financial strength to expand globally, enter surgical robotics, pursue strategic acquisitions, and develop home-based chronic care devices, reinforcing its patient-centred innovation and market leadership (Nielsen, 2019; Wu and Luo, 2010). Competitors like Philips (HealthSuite) and GE Healthcare (Edison) have shown that AI-enabled analytics and cloud-connected devices significantly improve adoption rates in hospitals.

Weakness -Opportunities (WO): -

Medtronic can reduce internal fragmentation by restructuring operations, focusing on core sectors, and strengthening product promotion alongside R&D, turning weaknesses into strategic advantages to boost competitiveness and innovation impact (Dargahi, Darrudi and Zalvand, 2019).

Strengths -Threats (ST): -

Medtronic can optimize supply chains and expand global manufacturing to reduce regional risks, while leveraging innovation leadership to set industry standards, mitigate competition, and enhance resilience and market influence (Chaudhuri, 2015; Nze-Ekpebie and Udealor, 2023). Abbott's Libre platform has disrupted the diabetes management market and captured millions of users

Weakness -Threats (WT): -

Medtronic should adapt to evolving regulations, treatment protocols, and market changes, using flexible product strategies and contingency planning to maintain performance, customer trust, and continuity during crises (Bajada et al., 2015; Carter, 2018). Philips' regulatory challenges after the ventilator recall show how operational weaknesses can escalate into legal and reputational threats.

2.4 Porter's Five Forces Framework on Medtronic

To remain competitive, Medtronic must understand the external pressures shaping the medical device industry. Porter's Five Forces highlights threats from entrants, substitutes, customers, suppliers, and rivalry that influence strategic decisions (Nielsen, 2019). As Holland and Bátiz-Lazo (2004) and Scott Morton (1997) note, these competitive forces are central to how healthcare firms position themselves globally.

1. **Threat of New Entrants (Moderate):**

The threat of new entrants is moderate because high capital needs, strict regulations, and complex manufacturing limit access, though well-financed or technologically advanced firms can still enter. This means established companies must keep investing in innovation and compliance to stay competitive (Scott Morton, 1997). These barriers also emphasise the strategic importance of patents and intellectual property in protecting market positions.



Figure 2: Healthcare Market Size 2024-2034 (USD Billion)

2. **Bargaining Power of Buyers (Low):**

Buyer power is relatively low for Medtronic because it is the sole producer of the Micra leadless pacemaker, reducing the leverage of patients, insurers, and healthcare providers (Shaygan et al., 2017). However, conventional pacemakers remain cheaper alternatives, and differences in patient needs—such as single- vs dual-chamber devices—limit Medtronic's dominance. Overall, buyer bargaining power is low and poses minimal competitive risk.

3. **Bargaining Power of Suppliers (High):**

Despite a global supplier base, Medtronic faces high supplier power due to dependence on specialized components like those for the Micra pacemaker. Switching suppliers is costly, and the risk of suppliers becoming competitors increases vulnerability (UK Essay, 2013). Effective supplier management and strategic partnerships are therefore critical to prevent production disruptions. Semiconductor shortages in 2021–22, for example, caused delays across Medtronic's manufacturing (Parker, T., Bloomberg).

Table 1: Supplier list of Medtronic

Supplier	**Type**	**Region**	**Role in Medtronic's Supply Chain**
Plexus Corp	Electronics Manufacturer	North America	Provides electronic manufacturing services for medical devices.
IntriCon Corp	Medical Device Manufacturer	North America	Supplies miniature medical components and devices.

Dassault Systèmes SE	Software Provider	Europe	Offers 3D design and simulation software for product development.
Celestica Inc.	Electronics Manufacturer	North America	Manufactures complex electronics and provides supply chain solutions.
Benchmark Electronics	Electronics Manufacturer	North America	Provides integrated electronics manufacturing services.
LISI	Components Supplier	Europe	Supplies precision components for medical devices.
TTM Technologies	Electronics Manufacturer	North America	Manufactures advanced printed circuit boards and interconnect solutions.
Vishay Inter technology	Component Supplier	Global	Provides electronic components like resistors and capacitors.
Microchip Technology	Semiconductor Supplier	Global	Supplies microcontrollers and analog semiconductors.
Berry Global Group	Packaging Supplier	Global	Provides medical packaging solutions.
Surmodics Inc.	Medical Device Supplier	North America	Supplies drug delivery and diagnostic components.
Varex Imaging Corporation	Imaging Components Supplier	North America	Provides X-ray imaging components.
Sinbon Electronics	Electronics Manufacturer	Asia	Manufactures interconnect solutions for medical devices.
COSMO Pharmaceuticals	Pharmaceutical Supplier	Europe	Supplies active pharmaceutical ingredients and finished dosage forms.

4. **Threat of Substitute (Low): -**

Medtronic faces a low-to-moderate threat from substitutes. Despite patented, specialized devices, alternative solutions can influence demand and pricing. Continued R&D and strategic acquisitions are needed to maintain differentiation and prevent customer switching.



Figure 4: First Quarter Final Results 2024 Fiscal Year Summary

5. Competitive Rivalry (High): -

Competitive rivalry in the pharmaceutical industry is high due to numerous global players and substantial fixed costs in R&D, production, and compliance. Continuous innovation and patent expirations drive heavy investment, increasing pressure to differentiate through products, marketing, and technology. Key competitors include Philips, Siemens Healthineers, and Abbott.



Figure 5: Leading medical technology Companies worldwide based on revenue in 2021(in billions U.S. Dollars)

2.5 Mendelow's Matrix for Stakeholder Mapping

Medtronic operates within a complex healthcare service ecosystem, where multiple stakeholders interact with varying levels of power, legitimacy, and urgency. According to Wu et al. (2019), stakeholders in healthcare can be grouped into leading, core, and supporting populations, each influencing healthcare outcomes differently.

Key Players -Leading stakeholders (high power, legitimacy, urgency):

Regulatory authorities (FDA, EMA), hospital administrators, and physicians hold the most influence over Medtronic, shaping market access through compliance, approvals, and adoption decisions (Wu et al., 2019). The adoption of platforms like GE Edison and Siemens Digital Ecosystems increases demand for integrated digital solutions.

Keep Informed -Core stakeholders (moderate-to-high influence):

Hospitals, insurers, and patients shape Medtronic's device adoption, while research centres support innovation (Rizk et al., 2021; Wu et al., 2019). Regulatory scrutiny, like FDA oversight after the Philips recall, influences digital and safety standards.

Keep Satisfied -Supporting stakeholders (lower power but enabling):

Suppliers, pharma partners, pharmacies, and payment platforms support Medtronic's value chain (Nielsen, 2019). Emerging actors like digital hospitals and online doctors align with its precision medicine strategy (Wu et al., 2019). Semiconductor shortages highlight supplier impact on production

Minimal Effort – Low Power and Low Interest

Low-power stakeholders, like the public and community groups, influence Medtronic through CSR and ethics expectations (Rizk et al., 2021; Wu et al., 2019). Success depends on engaging high-power stakeholders while maintaining broader ecosystem cooperation to support innovation, affordability, and trust.

Table 2: Classification results of stakeholders

Category	**Stakeholders**
Core stakeholders （22）	Physician; National Regulatory Authorities, Hospital Administrators

	Tertiary Hospitals, Pharmacists; Secondary Hospitals, Rehabilitation Institutions; Nursing Homes, Hospices, Nursing Staff; Community Service Centres, Contracted Medical Care Groups, Family Pension Groups, Family Doctors, Rehabilitation Physicians; Medical Research Centres, Independent Medical Laboratories; Medical Insurance Companies, Medical Insurance Department, Grassroots Regulatory Department; Patients, Family Members
Potential stakeholders （9）	Health Manager; Physician Medical Groups, Digital Hospital, Online Doctors; Medical Equipment Companies, Pharmaceutical Companies, Pharmacies; Third-Party Payment Platforms, Banks

2.6 Key Strategic Limitations & Digital Transformation Gaps

Despite its global leadership, Medtronic faces strategic gaps in digital transformation, as identified through PESTEL, TOWS, Porter's Five Forces, and stakeholder analysis (Kaplan et al., 2018; Shaw & Glaser, 2022):

1. **Fragmented Digital Ecosystem:** Separate platforms for diabetes, cardiovascular, and surgical care limit interoperability compared to competitors like Siemens and GE (Shaw & Glaser, 2022).
2. **Lagging Predictive Analytics:** AI-enabled monitoring is behind digital-first rivals, reducing support for proactive, outcome-based care (Ding et al., 2024).
3. **Need for Cloud-Integrated Monitoring:** Remote care platforms remain siloed, lacking unified cloud infrastructure for scalable patient monitoring (Chintala, 2025).
4. **Hardware-Focused Value Proposition:** Limited service-based offerings risk reduced differentiation as competitors adopt subscription models and AI analytics (Kaplan et al., 2018; Porter, 2014).
5. **Regulatory & Supply-Chain Pressures:** Complex global suppliers and weak digital traceability increase vulnerability, highlighting the need for real-time tracking and automated quality management (Musamih et al., 2025; HBR Analytics Services, 2022).

Strategic Digital Transformation Gaps

- Lack of a unified, interoperable digital ecosystem
- Underdeveloped predictive analytics and AI capabilities
- Need for scalable cloud platforms for integrated device monitoring (Williams et al., 2024)

- Value proposition still centred on hardware rather than digital services (Rodrigues, 2025)
- Insufficient real-time digital supply-chain and post-market surveillance tools (Alpert, 2013; Cheng, 2019).

These limitations highlight the need for a comprehensive digital transformation strategy centred on AI-driven remote monitoring, cloud integration, predictive analytics, and ecosystem partnerships

TASK 2 – DIGITAL TRANSFORMATION STRATEGY PROPOSAL

3.1 Proposed Digital Transformation Strategy for Medtronic

To address the digital transformation gaps identified in Task 1, this report proposes an integrated strategy titled: "AI-Enabled Remote Monitoring and Cloud Health Platform". This strategy aims to connect Medtronic's entire device ecosystem cardiac, diabetes, surgical, and neuroscience to a single cloud-based platform enhanced with predictive AI analytics.

The strategic objectives are:
- Deliver real-time patient diagnostics and automated early warnings.
- Enable clinicians to personalise therapies using AI-driven insights.
- Strengthen long-term customer relationships through digital services.
- Shift Medtronic's value proposition from hardware-based to hybrid "device + digital service".

Industry evidence supports this shift: Abbott's FreeStyle Libre, GE Edison, and iRhythm's AI cardiac monitoring demonstrate the competitive necessity of integrated remote-care platforms.

3.2 Strategic Analysis Using the Ansoff Matrix

The Ansoff Matrix helps Medtronic protect core markets while exploring growth via innovation, market expansion, and diversification. Leveraging its global presence, partnerships, and strong R&D pipeline, the framework supports navigating healthcare complexities and sustaining competitive advantage (Ansoff, 1957; Johnson et al., 2017; Siddiqui, 2021).

Market Penetration – Increasing adoption of existing devices through digital add-ons

Enhancing current products with digital features such as remote monitoring or data dashboards strengthens customer loyalty and increases utilisation of Medtronic's established portfolio. This aligns with strategic recommendations that digital enhancements can reinforce competitive advantage by deepening value within existing markets (Siddiqui, 2021; Johnson et al., 2017).

Product Development – AI-enabled upgrades to current devices

Integrating AI into existing technologies allows Medtronic to improve clinical accuracy, personalise treatment, and maintain its position as an innovation leader. Literature emphasises that product innovation drives long-term advantage in rapidly evolving medical technology sectors (Ansoff, 1957; Siddiqui, 2021).



Figure 5: Ansoff Matrix

Market Development – Expanding digitally into emerging regions

Using digital platforms to introduce Medtronic's portfolio into high-growth markets supports global scale and aligns with the company's continued investment in international expansion (Medtronic, 2024; DCF Modelling, 2024). This strategy leverages rising global demand and broadens access, reinforcing sustainable growth.

Diversification – Creating new digital health services

Developing digital health solutions such as virtual care or data-driven chronic disease programmes allows Medtronic to move beyond devices into service-based revenue models. This supports long-term competitiveness by reducing dependence on traditional hardware markets and responding to shifting global healthcare needs (Siddiqui, 2021).

3.3 Portfolio Prioritisation – BCG Matrix

Medtronic Divisional Analysis and Digital Investment Strategy

1. AI-enabled Cardiac Devices: Stars

This division is in a high-growth market with strong Medtronic share, driven by AI integration in cardiac rhythm and monitoring devices, which improves patient monitoring and reduces false alarms (Xu, Wang & Wei, 2025; Stifleur & Tison, 2023).

2. Surgical Instruments: Cash Cows

Medtronic holds a dominant share in mature surgical instrument markets, generating stable cash flow with moderate growth and lower capital requirements (CSIMarket, 2025; Doughty et al., 2020).

3. Diabetes Tech: Question Marks

Medtronic's diabetes division operates in a high-growth market but holds a lower market share due to strong competition from Abbott and Dexcom, making it a "Question Mark" that requires significant investment (Bekiari et al., 2022; CSIMarket, 2025).

4. Low-tech Legacy Products: Dogs

Low-tech legacy products operate in saturated, low-growth markets with minimal differentiation and low market share, often generating minimal profit and targeted for efficiency improvements or divestiture (CSIMarket, 2025).

Justification for Digital Investment

According to the BCG Matrix, cash from "Cash Cows" should fund high growth "Stars" and selective "Question Marks" to secure long-term competitiveness.

- **Stars – AI-enabled cardiac devices:** Highest digital investment priority. Funding should enhance AI algorithms, cloud analytics, and device connectivity to maintain technological leadership (Xu, Wang & Wei, 2025).
- **Question Marks – Diabetes TechT**arget digital upgrades needed to close gaps in CGM integration, automated insulin delivery, and patient-facing apps, helping this division evolve into a "Star" (Bekiari et al., 2022).
- **Cash Cows – Surgical instruments & Dogs – Legacy low-tech products:** Minimal product R&D investment. Digital spending should improve operational efficiency through supply-chain analytics, smart manufacturing, and inventory optimisation (Doughty et al., 2020).

3.4 Business Model Disruption Theory Application

Healthcare is rapidly disrupted by digital technologies. Connected devices (IoMT) enable continuous monitoring and timely interventions (Faruque & Rahman, 2024; Prentice & Duncan, 2017), while consumer health platforms improve engagement, adherence, and self-management (Psyllidis et al., 2025; Waqas & Ahmad,

2023). AI-driven predictive diagnostics support early detection, personalized care, and efficient delivery (Gupta & Kumari, 2023; Hussain et al., 2025).

Disruption frameworks help Medtronic respond strategically. The Two Differentials framework identifies opportunities in low-end and new markets (Christensen, 1997; Eyal & Barel, 2018), while the Disruptive Business Model Map guides value creation through digital innovation, data use, and customer engagement (Chaudhry, 2019; Westerman, Bonnet & McAfee, 2014; Markides, 2025). These approaches support Medtronic's shift from device sales to AI-enabled, patient-centric ecosystems, enhancing competitive advantage (Gomes & de Vasconcelos, 2023).

3.5 New Value Proposition (VP)

Medtronic's new value proposition focuses on remote care, early detection, personalized therapy, and reduced hospital visits, designed to meet modern patient needs and healthcare system demands (Christensen, 1997; Eyal & Barel, 2018). Using Value Proposition Generatives, these features can be expanded as follows:

- **Remote care:** Continuous patient monitoring via connected devices and mobile health platforms, enabling proactive interventions and virtual consultations (Faruque & Rahman, 2024; Prentice & Duncan, 2017).
- **Early detection**: Predictive analytics to identify potential health issues before symptoms emerge, improving clinical outcomes and reducing emergency events (Gupta & Kumari, 2023; Psyllidis et al., 2025).
- **Personalized therapy:** Customized treatment plans based on real-time patient data, history, and predictive insights to enhance adherence and effectiveness (Waqas & Ahmad, 2023).
- **Reduced hospital visits**: Integration of home-based monitoring and digital health tools to minimize in-person visits while maintaining care quality and patient satisfaction (Din, 2024).

Medtronic's value proposition positions it as a patient-centric, digitally enabled healthcare provider, combining advanced technology with efficiency and improved outcomes to sustain long-term competitive advantage (Gomes & de Vasconcelos, 2023; Westerman et al., 2014).

3.6 Value Network Design

Medtronic's digital transformation relies on a robust value network to deliver connected, patient-centric healthcare solutions. Key partners include:

- **Cloud providers (Azure, AWS):** Enable secure, scalable data storage, processing, and real-time analytics for connected medical devices.

Collaborations with major providers help implement robust, data-driven infrastructure (Gupta & Kumari, 2023).

- **AI companies:** Support development of predictive diagnostics, personalized therapy algorithms, and advanced device intelligence. This allows for rapid development of AI-enabled technologies that integrate into clinical workflows (Psyllidis et al., 2025; Waqas & Ahmad, 2023).
- **Hospital systems:** Facilitate integration of Medtronic's digital solutions into clinical workflows, enhancing adoption and patient outcomes. Partnerships ensure that technology aligns with the health system's operational needs and improves care efficiency (Prentice & Duncan, 2017).
- **Cybersecurity firms:** Ensure data privacy, regulatory compliance, and protection against cyber threats in a highly connected ecosystem. This is critical for safeguarding sensitive medical data and ensuring the resilience of the entire network (Faruque & Rahman, 2024).

3.7 Strategic Position – Bowman's Clock & Generic Strategy

Medtronic's digital transformation combines affordability in emerging markets with high-value innovation in developed regions (WAITIMU, 2024).

- **Hybrid (3):** In emerging markets like India, Medtronic provides affordable services and devices, balancing cost efficiency with essential quality.
- **Differentiation (4):** In developed markets, high perceived value arises from cutting-edge innovation, R&D, and advanced services, such as robotic surgery and AI-enabled cardiac devices.
- **Focused Differentiation (5):** Specialized, high-value solutions are offered to niche patient segments with premium pricing, emphasizing personalized care and technological superiority.



This multi-layered positioning enables Medtronic to deliver better patient outcomes while maintaining technology leadership, ensuring sustained competitive advantage in a globally diverse healthcare landscape.

3.8 Balanced Scorecard (Strategic KPIs)

KPIs for:

1. **Financial Perspective**

- Return on Investment (ROI): Medtronic reported a net income of ~US $4.66 billion for FY2025, with revenue of ~US $33.5 billion, reflecting sustained profitability and value creation.
- Revenue Growth & Digital Business Impact: Total revenue increased ~4.9% organically in FY25, with continued expansion in high-growth device segments like cardiac ablation and diabetes technologies.
- Operating & Cash Flow Strength: Operating profit expanded, and Medtronic generated ~US $7.0 billion in operating cash flow in FY25, supporting reinvestment and shareholder returns.

2. Customer Perspective

- Patient Reach & Service: Medtronic served ~79 million+ patients globally in FY25, indicating broad clinical adoption.
- Product Quality & Satisfaction Proxy: The company reported a ~34% reduction in aggregate product complaint rate, exceeding internal quality targets this reduction correlates with improvements in patient and clinician experience.
- Device Adherence Indicators: Continued double-digit growth in segments like diabetes (e.g., insulin delivery) reflects strong ongoing device utilization and adherence trends in clinical practice.

3. Internal Processes Perspective

- Faster Diagnosis & Workflow Efficiency: Medtronic's investment in AI-enabled diagnostics and robotics (e.g., Hugo™ RAS, BrainSense™) supports faster clinical decision-making and procedural precision, though specific speed metrics are proprietary.
- Uptime & Reliability: Product reliability is reflected in lower complaint rates and strong segment performance, with continuous mid-single-digit revenue growth across major device portfolios.

4. Learning & Growth Perspective

- AI & Training Investments: Medtronic trained >1.15 million healthcare professionals over recent years to improve application of its technologies in clinical settings (with ongoing goals to exceed this).
- Innovation Output & R&D: The company invested ~US $2.7 billion in R&D in FY25, with 200+ product regulatory approvals across major geographies reflecting strong innovation pipeline performance.
- Innovation Culture: ~83% of employees agree Medtronic puts patients first, illustrating alignment of culture with mission-driven innovation.

6. Revenue Enhancements & Benefits:

Medtronic's platform transforms the company into a healthcare ecosystem leader, integrating devices, analytics, and digital services to boost efficiency, reduce costs, and enable reinvestment in innovation (Fan et al., 2024).

Table 3 : Medtronic Digital Initiatives Driving Growth (FY2025–FY2026)- Self Created

Growth Area	Key Metrics & Achievements
Cardiac Ablation Solutions	Revenue ↑ 50%; U.S. sales ↑ 72% due to innovations like pulsed field ablation technology
Diabetes Business	Q4 FY2025 revenue: $728M; YoY growth: 10.4% (strong demand for diabetes management solutions)
Operational Efficiency	Operating profit ↑ 13%; Operating margin ↑ 70 basis points (Q1 FY2026)



Figure 6: Medtronic Digital Initiatives Contribution

3.9 Justification for Why This Strategy Ensures Sustained Competitive Advantage

Medtronic's strategy ensures sustained competitive advantage by leveraging resources and capabilities that are implicitly valuable, rare, inimitable, and well-organized:

- **Valuable:** Medtronic's diversified portfolio of advanced medical technologies addresses over 70 health conditions and delivers solutions globally through a workforce of more than 95,000 employees in over 150 countries, resulting in broad clinical impact and stronger market demand (Medtronic, 2025).
- **Rare:** The company maintains a large and active patent portfolio (tens of thousands of patent matters) and invests heavily in research and development approximately $2.7 billion in FY25 providing proprietary technologies that are not widely available across competitors (Medtronic, 2025).
- **Inimitable:** Medtronic's sustained R&D expenditure and its integration of cutting-edge technology such as AI-enabled device enhancements and robotic-assisted surgery systems alongside deep clinical relationships with healthcare providers, underpin capabilities that are complex and costly to replicate (Industry Intel, 2025).
- **Organized:** The company's extensive global network, structured R&D operations, and coordinated clinical collaborations ensure efficient exploitation of its technological and intellectual property strengths, enabling rapid translation of innovation into commercial products (Medtronic, 2025).

Conclusion: By combining valuable health outcomes, rare intellectual assets, inimitable technological and clinical capabilities, and a well-organized global network,

Medtronic sustains a competitive advantage that rivals find difficult to match, supporting long-term growth and leadership in medical technology (Medtronic, 2025; Industry Intel, 2025).

TASK 3 – IMPLEMENTATION PLAN & BUDGETING

4.1 Implementation Roadmap (Timeline)

Year 1 – Pilot AI Platform & Partnerships

- Develop and test the AI platform in key therapeutic areas (e.g., cardiac, diabetes).
- Establish partnerships with leading hospitals, research institutions, and digital health firms.
- Conduct pilot programs to validate clinical effectiveness, data integration, and patient outcomes.
- Gather user feedback and regulatory insights to inform platform refinement.

Year 2 – Launch in US & EU

- Obtain necessary regulatory approvals (FDA, CE marking) for market entry.
- Launch commercially in the US and EU, targeting major hospitals and clinics.
- Implement marketing and clinician education programs to drive adoption.
- Monitor performance metrics: patient engagement, device adherence, and clinical outcomes.

Year 3 – Scale Globally

- Expand into Asia-Pacific, Latin America, and other high-growth markets.
- Strengthen local partnerships and establish distribution networks in new regions.
- Scale AI platform capabilities, integrating more therapeutic areas and multi-device data.
- Ensure compliance with local regulations and data privacy requirements globally.

Year 4 – Optimisation & New Features

- Optimise platform performance using AI analytics from global user data.
- Introduce new features, such as predictive analytics, remote monitoring, and personalized care recommendations.
- Continuously improve patient outcomes and operational efficiency.
- Evaluate ROI, customer satisfaction, and global impact, preparing for next-generation AI platform upgrades



4.2 Resource Requirements

To implement a scalable AI platform, Medtronic is mobilizing significant resources, underpinned by a **$2.7 billion annual R&D budget** (Medtronic, 2024) and strategic alliances with technology leaders.

1. Talent Resources

- **AI Engineers & Data Scientists:** Recruitment prioritizes bioengineers capable of integrating 'Human-in-the-Loop' systems. The focus is on bridging the gap between clinical workflows and edge-computing platforms like NVIDIA Holoscan (NVIDIA, 2023).
- **Regulatory Specialists:** Teams are expanding to navigate the divergence between the **EU AI Act** and **FDA** frameworks. Specialists now require data literacy to manage 'Post-Market Surveillance' (PMS) and detect model drift, a critical requirement for ensuring long-term algorithm safety (Team Consulting, 2025).

2. Technology Infrastructure

- **Cloud & Edge Computing:** Medtronic has integrated the **NVIDIA Holoscan** and **IGX** platforms into the GI Genius™ system. This hybrid architecture processes high-volume endoscopic data at the 'edge' (on-device) to reduce latency while leveraging cloud connectivity for federated learning updates (NVIDIA, 2023).
- **Cybersecurity:** Adopting a **Zero Trust Architecture (ZTA)** is essential to secure the 'Internet of Medical Things' (IoMT). This approach assumes no device

is safe by default and requires continuous validation of every user and legacy insulin pump or cardiac device to mitigate ransomware risks (Cognizant, 2025).

3. Financial Investment

- **R&D Budget:** Medtronic allocated **$2.7 billion** in FY24 to drive organic innovation, specifically targeting data-driven therapies in the Cardiovascular and Neuroscience portfolios (Medtronic, 2024).
- **Strategic Partnerships:** The strategy has shifted from pure acquisition to licensing. A notable example is the **$100 million upfront payment** to Cosmo Pharmaceuticals to secure exclusive global rights for the GI Genius AI platform, plus double-digit royalties on net sales (Fierce Biotech, 2023).

4.3 Risk Analysis

Risk	Impact	Mitigation Strategy
Regulatory barriers in emerging markets	High	Build strong local compliance teams, collaborate with regulators early.
High R&D costs & uncertain ROI	Medium	Stage-gate investment model, focus on scalable platforms first.
Cybersecurity threats in digital health platforms	High	Invest in robust cybersecurity frameworks (Chotia et al., 2023).
Competition from rivals (Johnson & Johnson, Abbott, Stryker)	High	Differentiate via AI-driven innovation and stronger partnerships.
Adoption resistance from healthcare providers	Medium	Training centers, incentives, and co-development partnerships.

4.4 Financial Budgeting

Category	Year 1 (£)	Year 2 (£)	Year 3 (£)	Notes
R&D	150,000	50,000	50,000	Prototype development, testing, iterations
Software Development	200,000	120,000	100,000	Backend, mobile apps, updates, bug fixes
Device Integration	100,000	60,000	40,000	Hardware-software integration, QA
Marketing & Partnerships	80,000	100,000	120,000	Launch campaigns, B2B/B2C partnerships
Training & Onboarding	20,000	15,000	15,000	Employee and partner training programs
Total Costs	550,000	345,000	325,000	Sum of above categories

Projected ROI Over 3 Years

Assuming **revenues** from product sales, subscriptions, or services:

Year	Projected Revenue (£)	Total Costs (£)	Net Profit (£)	ROI (%)
Year 1	300,000	550,000	-250,000	-45%
Year 2	600,000	345,000	255,000	74%
Year 3	1,000,000	325,000	675,000	208%

Insights:

- Initial losses in Year 1 are expected due to high upfront R&D and development costs.
- ROI improves significantly from Year 2 as the product gains market traction.
- By Year 3, scaling operations and marketing boosts revenue, resulting in strong profitability.

4.6 Success Measurement – Balanced Scorecard Metrics

Perspective	Objective	Key Performance Indicator (KPI)	Target / Benchmark
Financial	Increase revenue from digital services	Digital service revenue	$5 million by Year 3
	Optimize operational costs	Cost per device integration	10% reduction YoY
Customer	Enhance patient satisfaction	Patient satisfaction score (survey-based)	90% positive rating
	Improve service accessibility	% of patients served digitally	80% adoption rate
Internal Processes	Increase device reliability	Device downtime	20% reduction
	Improve diagnostic accuracy	Early detection success rate	30% improvement
Learning & Growth	Upskill staff and partners	Training completion rate	100% within 6 months
	Foster innovation	Number of process/product improvements implemented	5 major innovations/year

Explanation:

- Financial metrics track the monetary success and cost efficiency of your project.
- Customer metrics focus on patient satisfaction, adoption rates, and service quality.
- Internal Process metrics measure operational performance, such as device uptime and diagnostic accuracy.
- Learning & Growth metrics capture organizational development, including staff training and innovation outputs

TASK 4 – REFLECTIVE ANALYSIS

5.1 Overview of Reflective Practice

Reflective learning is the process of critically examining experiences to gain insights, develop understanding, and inform future actions. In a strategic context, reflective practice allows learners to:

- Identify patterns and relationships between theory and practice.
- Improve decision-making by considering past outcomes.
- Develop self-awareness and adaptability, key traits for strategic thinking.

By systematically reflecting, students can bridge the gap between academic knowledge and practical application, enhancing both personal and professional growth.

5.2 Compare Three Reflective Models

Model	Description	Strengths	Limitations
Gibbs' Reflective Cycle	Structured 6-stage process: Description → Feelings → Evaluation → Analysis → Conclusion → Action Plan	Encourages detailed reflection including emotional and evaluative aspects; provides clear guidance for academic work	Can be rigid; time-consuming; may overemphasize process over insight
Kolb's Experiential Learning Cycle	Four-stage cycle: Concrete Experience → Reflective Observation → Abstract Conceptualization → Active Experimentation	Emphasizes learning from experience; links theory to practice; suitable for iterative skill development	Less emphasis on emotions; can be abstract for beginners; may overlook immediate action planning
Rolfe et al. Model	Simple framework: What? → So What? → Now What?	Quick, practical; easy to apply in real-time; focuses on action outcomes	Lacks depth for academic reflection; limited guidance on emotional or analytical aspects

5.3 Justification for Choosing a Model

For this module, **Gibbs' Reflective Cycle** is selected because:

- It supports deeper academic reflection, combining emotional insight and structured evaluation.
- It aligns with the module's focus on strategic tools and critical analysis.
- The structured stages ensure that both learning outcomes and future actions are systematically addressed.

5.4 Application of Chosen Model to Your Module Learning

Using Gibbs' model, the following reflection covers key learning moments from lectures, seminars, literature reviews, and practical tool usage.

Description: Throughout the module, I engaged with various strategic management concepts, including environmental scanning tools (PESTEL, SWOT), portfolio models (BCG, Ansoff), stakeholder analysis, and Balanced Scorecard frameworks. Activities included lectures, seminars, case studies, and the development of a comprehensive digital strategy for Medtronic.

Feelings: Initially, I felt overwhelmed by the number of strategic frameworks and their conceptual overlap. However, as the module progressed, I gained confidence in selecting and applying appropriate tools. Group seminars helped me recognise gaps in my reasoning, while literature reviews improved my academic depth. I felt increasingly motivated as I saw how these tools integrated into real-world strategic decision-making.

Evaluation: Positive experiences included developing stronger analytical skills by applying frameworks to Medtronic. The literature review enhanced my ability to critique sources and connect theory with practice. Group discussions exposed me to diverse viewpoints, helping me identify blind spots in my analysis. Challenges included distinguishing when to use certain tools, avoiding overly descriptive analysis, and synthesising large amounts of data into strategic recommendations. However, these challenges ultimately strengthened my understanding.

Analysis: The use of tools such as PESTEL, SWOT/TOWS, Ansoff Matrix, BCG Matrix, Mendelow's Matrix, and Balanced Scorecard significantly improved my ability to structure strategic problems. Literature highlighted the importance of digital transformation in med-tech, reinforcing my understanding of industry pressures.

Seminars illustrated that strategic thinking requires both structured analysis and the ability to interpret ambiguous information. This aligns with Kolb's view of learning as iterative, though Gibbs' structure helped me dive deeper into evaluation.

Conclusion: I realised that strategic analysis is not simply applying tools, but critically interpreting insights and connecting them to organisational capabilities and competitive environments. The reflective process highlighted how my analytical and critical thinking skills improved throughout the module.

Action Plan

• Continue practising strategic frameworks using real companies to strengthen judgement.

• Improve synthesis skills by summarising complex insights more succinctly.

• Engage more actively in academic reading to deepen theoretical understanding.

• Explore advanced strategy literature on digital transformation to enhance future employability.

6. CONCLUSION

This report shows that Medtronic can strengthen its competitive position by applying strategic management frameworks effectively. Environmental tools such as PESTEL and SWOT identified key technological and regulatory pressures shaping the med-tech landscape (Johnson et al., 2020). Strategic planning models—including the Ansoff Matrix, BCG Matrix, and stakeholder analysis—highlighted opportunities to expand Medtronic's digital health capabilities (Porter, 1985; Lynch, 2018).

The proposed digital transformation strategy, supported by financial planning, risk assessment and a Balanced Scorecard, demonstrates how Medtronic can enhance device performance and generate new digital service revenues. The organisation's strong capabilities meet the VRIO criteria, indicating a sustained competitive advantage (Barney, 1991).

Reflective learning using Gibbs' (1988) model improved understanding of strategic tools and strengthened critical analysis, reinforcing the value of experiential learning (Kolb, 1984). Overall, the project concludes that Medtronic is well positioned to scale its digital ecosystem and maintain long-term competitiveness through evidence-based strategic decision-making.

References:

Medtronic. (2025). Key Facts. Available at: https://www.medtronic.com/uk-en/our-company/key-facts.html [Accessed 29 July 2025].

Pharmaceutical Technology. (n.d.). Medtronic Plc. Available at: https://www.pharmaceutical-technology.com/contractors/pharma-logistics-supply-chain/medtronic-plc/ [Accessed 29 July 2025].

Carter, J., 2018. A Strategic Audit of Medtronic PLC.

Nielsen, C., 2019. Valuation of the company Medtronic.

Holland, S. and Bátiz-Lazo, B., 2004. The global pharmaceutical industry. General Economics and Teaching, 405002, pp.1-24.

Hoveling, T., Svindland Nijdam, A., Monincx, M., Faludi, J. and Bakker, C. (2024) Circular economy for medical devices: Barriers, opportunities and best practices from a design perspective. Resources, Conservation and Recycling, 208, Article 107719. doi: 10.1016/j.resconrec.2024.107719

Fox, F., Hayes, J., Whelan, B., Casey, D. & Connolly, M., 2024. Key factors impacting a medical ventilator supply chain during the COVID-19 pandemic: Lessons for pandemic preparedness. Cambridge University Press published online 12 April.

Rossi, M. and Rehman, S., n.d. *Integrating Artificial Intelligence Into Telemedicine: Evidence, Challenges, and Future Directions*.

“Key Facts” page (Medtronic, 2025) + 2025 press release on London AI/robotics hub.

“Key Facts” page (Medtronic, 2025) + press release about business separations.

Medtronic LABS “Healthcare Access” page, Medtronic corporate “Key Facts” or “Our Impact” pages.

HBR Analytics Services (2022) *Digital Transformation Refocused: New Goals Require New Strategies*. Red Hat.

Baker, D. (2018) ‘Medtronic continues to push outcome-based contracts: 5 things to know’, *Becker’s Spine Review*, 2 April.

Chintala, A. (2025) ‘AI-Powered Predictive Analytics in Chronic Disease Management: Regulatory and Ethical Considerations’, *ResearchGate*

Ding, S. *et al.* (2024) ‘Impact of Artificial Intelligence-Enhanced Insertable Cardiac Monitors on Device Clinic Workflow and Resource Utilization’, *JACC: Clinical Electrophysiology*, 10(4), pp. 385–395.

Kaplan, R. S., Porter, M. E., Feeley, T. W. and Hernandez, A. (2018) ‘Medtronic: Navigating a Shifting Healthcare Landscape’, *Harvard Business School Case*, No. 718-471, January (Revised June 2018).

Musamih, I. *et al.* (2025) ‘Enhanced Traceability and Transparency in Medical Supply Chain Management Using Blockchain-Based Customized Smart Contracts’, *ResearchGate* (Preprint/Review).

Porter, M. E. (2014) ‘How Smart, Connected Products Are Transforming Competition’, *Harvard Business Review*, November, pp. 65-88.

Shaw, S. and Glaser, J. (2022) ‘Digital Transformation Success: What Can Health Care Providers Learn from Other Industries?’, *NEJM Catalyst Innovations in Care Delivery*, 3(7).

Williams, E. *et al.* (2024) ‘Cloud technology and capsule endoscopy: A single-center users’ experience of remote online video analysis and reporting’, *International Journal of Surgery Protocols*, 35(1), pp. 29–33

Rodrigues, N. J. (2025) ‘Predictive Analytics and Artificial Intelligence: Advancing Business Analytics in the Medical Devices Industry’, *European Journal of Computer Science and Information Technology*, 13(41), pp. 75-90.

Cheng, A. (2019) *Digital health applications in medical device post market surveillance* [Presentation]. ESC Cardio.

Bekiari, E., et al. (2022). Automated Insulin Delivery: Benefits, Challenges, and Perspectives. *Diabetes Care*, 45(12), pp. 3058-3072.

CSIMarket. (2025). Medtronic Plc Market share relative to its competitors, as of Q3 2025.

Doughty, A. S., et al. (2020). Assessing organic material on single-use vessel sealing devices. *Surgical Endoscopy*, 34, pp. 5312-5318.

Stifleur, R. S. & Tison, G. H. (2023). Wearable Devices in Cardiovascular Medicine: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, 75(14), pp. 1705-1718.

Xu, J., Wang, Y. & Wei, M. (2025). From Clinic to Cloud: Efficacy of AI-Assisted Remote Monitoring of Cardiac Implantable Electronic Devices. *Journal of the American Heart Association*.

Christensen, C. M. (1997). *The innovator's dilemma: When new technologies cause great firms to fail*. Harvard Business School Press.

Din, S. M. S. U. (2024). Impact of Remote Patient Monitoring Systems on Nursing Time, Healthcare Providers, and Patient Satisfaction in General Wards. *Cureus*, 16(6), e255710.

Eyal, O., & Barel, O. (2018). *Digital transformation and disruption of the health care sector*. In *Disruptive Innovation in Business and Finance in the Digital World*, Emerald Publishing Limited.

Faruque, I., & Rahman, M. A. (2024). Impact of Connected Healthcare Systems on Patient Safety. *Cureus*, 16(5), e12068690.

Gomes, M., & de Vasconcelos, J. (2023). Digital Technologies Impact on Healthcare Delivery: A Systematic Review. *Journal of Open Innovation: Technology, Market, and Complexity*, 5(4), 95.

Gupta, A., & Kumari, M. (2023). A review on innovation in healthcare sector (telehealth, AI, big data, IoT, ML, deep learning). *Sustainability*, 15(8), 6655.

Prentice, K., & Duncan, M. J. (2017). Remote patient monitoring via non-invasive digital technologies: an overview of the current landscape. *Applied clinical informatics*, 8(1), 246-261.

Waitimu, f., 2024. *Factors affecting the adoption of competitive strategies by private healthcare facilities in nairobi, kenya* (doctoral dissertation, strathmore university).

Medtronic (2025) *Key facts*, Medtronic plc. Available at: https://www.medtronic.com/uk-en/our-company/key-facts.html .

Statista (2025) *Medtronic statistics and facts* [Online]. Available at: https://www.statista.com/topics/10864/medtronic/

Industry Intel (2025) *Medtronic LinkedIn highlights innovation and strategic partnerships*

Cognizant (2025) 'Zero Trust' and healthcare: a cybersecurity blueprint. Available at: https://www.cognizant.com/us/en/insights/insights-blog/zero-trust-and-healthcare-a-cybersecurity-blueprint.

Fierce Biotech (2023) Medtronic doubles down on endoscopy AI with $200M Cosmo deal. Available at: https://www.fiercebiotech.com/medtech/medtronic-doubles-down-endoscopy-ai-partnership-inking-200m-deal-cosmo-pharmaceuticals.

Medtronic (2024) Fiscal Year 2024 Annual Report. Available at: https://investorrelations.medtronic.com.

NVIDIA (2023) Medtronic and NVIDIA Collaborate to Build AI Platform for Medical Devices. Available at: https://nvidianews.nvidia.com/news/medtronic-and-nvidia-collaborate-to-build-ai-platform-for-medical-devices.

Team Consulting (2025) Regulation of AI in healthcare: navigating the EU AI Act and FDA. Available at: https://www.team-consulting.com/insights/regulation-of-ai-in-healthcare-navigating-the-eu-ai-act-and-fda/.